사렙타 테라퓨틱스(SRPT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $20.11 (-2.71%), 시가총액 $1.79B, PER 48.37, 52주 범위 $11.93 ~ $43.01.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and…
사렙타 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
사렙타 테라퓨틱스의 현재 주가는 $20.11 (-2.71%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
사렙타 테라퓨틱스의 시가총액은 약 $1.79B입니다. PER은 48.37입니다.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic…